510(k) Report

De Novo · Granted

Granted

Active Anthrax DetectTM Plus Rapid Test

DEN220044De NovoGranted Feb 3, 2023210-day reviewClass II21 CFR 866.3046

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

InBios International, Inc. · QUU Simple In Vitro Diagnostic Device For The Detection Of Secreted Proteins From Bacillus Spp. In Human Clinical Samples

Granted on Feb 3, 2023 as a new device type through De Novo after a 210-day review. 1 later device descends from it.

Decided
Feb 3, 2023
Review
210 days
Class
Class II
Product code
QUU
Recalls
None

1 later device descends from it, 1 citing it directly.

Descendants, by year cleared 2023: 1 descendant cleared2020202220242026
  1. This deviceDEN220044 Active Anthrax DetectTM Plus Rapid TestInBios International, Inc. · 2023
  2. Descendant · cites it directly · 0 of its ownK232545 The SensiTox B. anthracis Toxin TestFirst Light Diagnostics, Inc. · 2023

Most influential descendants

Showing 1 of 1 · See all
  • K232545The SensiTox B. anthracis Toxin TestFirst Light Diagnostics, Inc. · 2023 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
0 (this device)DEN220044Active Anthrax DetectTM Plus Rapid TestInBios International, Inc.2023—
+1K232545The SensiTox B. anthracis Toxin TestFirst Light Diagnostics, Inc.2023—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202310
FIG. 1 — Lineage of DEN220044, 2023–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA De Novo database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QUU? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QUU device

  1. #1 K232545 The SensiTox B. anthracis Toxin Testscore 6.4 · 1 generation · no Class I recall
Get a 510(k) Report

Does it have a predicate?

De Novo decisions do not claim a predicate device.

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K232545The SensiTox B. anthracis Toxin TestFirst Light Diagnostics, Inc.20230

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Of its descendants, K232545 (First Light Diagnostics, Inc., 2023) has gone furthest, with 0 descendants of its own.

How does its category compare?

All QUU devices

QUU Simple In Vitro Diagnostic Device For The Detection Of Secreted Proteins From Bacillus Spp. In Human Clinical Samples: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · QUU

2in 2023

2023: 2
2007high 2 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QUU

Too few QUU 510(k)s in any year since 2007 to give a median.

Recalls per year · QUU

No recall names QUU since 2007.

Adverse event reports per year · QUU

No MAUDE report names QUU since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20210—00
20220—00
20232—00
20240—00
20250—00
20260—0—

What is it indicated for?

The Active Anthrax Detect Plus Rapid Test point-of-care diagnostic test for pulmonary anthrax is an in vitro immunochromatographic device for use as an aid in the diagnosis of inhalation anthrax. It provides visual and rapid qualitative detection of lethal factor of Bacillus anthracis (B. anthracis). The test can be used to test serum and venous whole blood (dipotassium EDTA, sodium citrate, and sodium heparin). The assay is indicated for testing samples…

Read the full statement (236 words)

The Active Anthrax Detect Plus Rapid Test point-of-care diagnostic test for pulmonary anthrax is an in vitro immunochromatographic device for use as an aid in the diagnosis of inhalation anthrax. It provides visual and rapid qualitative detection of lethal factor of Bacillus anthracis (B. anthracis). The test can be used to test serum and venous whole blood (dipotassium EDTA, sodium citrate, and sodium heparin). The assay is indicated for testing samples from individuals who have signs and symptoms consistent with inhalation anthrax and a likelihood of exposure. This test is intended for use by military personnel, medical, and/or healthcare professionals only. The diagnosis of B. anthracis infection must be based on history, signs, symptoms, exposure likelihood, and additional laboratory evidence. A positive Active Anthrax Detect Plus Rapid Test result is presumptively diagnostic for B. anthracis infection. The definitive identification of B. anthracis from blood samples requires additional testing and confirmation procedures in consultation with public health or other authorities for whom reports are required. Testing should be performed and reported in accordance with current guidelines provided by the appropriate public health authorities. The level of lethal factor present in blood from individuals with early systemic infection is unknown. Negative results do not preclude infection with the biothreat microbial agents targeted by the device and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions. This assay is for Rx use.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “DEN220044: Active Anthrax DetectTM Plus Rapid Test.” Lineage record from FDA De Novo data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/DEN220044

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026